Lisa K. McNeil

University of Liverpool — United Kingdom

Immunology and Microbiology · Life Sciences

31h-index2.8kcitations84works14.12yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Immunotherapy and Immune Responses(25), Cancer Immunotherapy and Biomarkers(20), T-cell and B-cell Immunology(16), Bacterial Infections and Vaccines(15), Pneumonia and Respiratory Infections(14)

Publications83 total

an AMR-Lung/European Lung Foundation global patient survey
Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT)·2025Open Access
1317 AMPLIFY-7P Phase 2: T cell responses induced by ELI-002 7P, a lymph node-targeted amphiphile therapeutic cancer vaccine in patients with KRAS mutated pancreatic ductal adenocarcinoma
2025Open Access
From a patient's experience: why healthcare professionals must consider aspergillosis
Breathe·2025Open Access
Lung Health and Respiratory Syncytial Virus: Podcast of a Patient–Physician Discussion Based on Insights from a Patient Advisory Board Meeting
Infectious Diseases and Therapy·2025Open Access
Lymph node-targeted, mKRAS-specific amphiphile vaccine in pancreatic and colorectal cancer: phase 1 AMPLIFY-201 trial final results
Nature Medicine·2025· 18 citedOpen Access
Patients’ perspectives on antimicrobial resistance in chronic respiratory disease: an AMR-Lung/European Lung Foundation global patient survey
ERJ Open Research·2025Open Access
Respiratory physiology: a patient perspective
European Respiratory Society eBooks·2025
Dental extraction planning in head and neck cancer patients: a qualitative study to understand pre-radiotherapy management
Journal of Radiotherapy in Practice·2025Open Access
Amphiphile-engineered DNA adjuvants stimulate strong type I IFN production in lymph nodes via cytosolic danger-sensing to induce potent cellular and humoral immunity in mice and non-human primates
2024Open Access
1473 AMPLIFY-7P phase 1a: lymph node-targeted amphiphile therapeutic cancer vaccine in patients with high relapse risk KRAS mutated pancreatic ductal adenocarcinoma and colorectal cancer
2024· 3 citedOpen Access
AMPLIFY-7P, a first-in-human safety and efficacy trial of adjuvant mKRAS-specific lymph node targeted amphiphile ELI-002 7P vaccine in patients with minimal residual disease–positive pancreatic and colorectal cancer.
Journal of Clinical Oncology·2024· 9 cited
Abstract CT107: Durable immunogenicity of ELI-002 2P in AMPLIFY-201: Lymph node targeted mKRAS-specific amphiphile vaccine in pancreatic and colorectal cancer
Cancer Research·2024· 1 cited
Correction: Neutrophil killing of Staphylococcus aureus in diabetes, obesity and metabolic syndrome: a prospective cellular surveillance study
Diabetology & Metabolic Syndrome·2024Open Access
Abstract C092: T cell responses and clinical outcomes in pancreatic and colorectal cancer patients with minimal residual disease in AMPLIFY-201, a phase 1 trial of a first-in-class amphiphile lymph node targeted mutant KRAS vaccine
Cancer Research·2024
Lymph-node-targeted, mKRAS-specific amphiphile vaccine in pancreatic and colorectal cancer: the phase 1 AMPLIFY-201 trial
Nature Medicine·2024· 192 citedOpen Access
656 ELI-002 immunotherapy induces broad polyfunctional T cell responses in subjects with high relapse risk KRAS mutated pancreatic ductal adenocarcinoma and colorectal cancer
Regular and Young Investigator Award Abstracts·2023· 1 citedOpen Access
Lymph node targeted multi-epitope subunit vaccine promotes effective immunity to EBV in HLA-expressing mice
Nature Communications·2023· 51 citedOpen Access
AMPLIFY-201, a first-in-human safety and efficacy trial of adjuvant ELI-002 2P immunotherapy for patients with high-relapse risk with KRAS G12D- or G12R-mutated pancreatic and colorectal cancer.
Journal of Clinical Oncology·2023· 17 cited
Supplementary Table from An Empirical Antigen Selection Method Identifies Neoantigens That Either Elicit Broad Antitumor T-cell Responses or Drive Tumor Growth
2023Open Access
Data from An Empirical Antigen Selection Method Identifies Neoantigens That Either Elicit Broad Antitumor T-cell Responses or Drive Tumor Growth
2023Open Access
page 1 of 5Next →

Frequent Co-authors

Annaliesa S. Anderson(16), Kathrin U. Jansen(14), Ellen Murphy(8), Peter C. DeMuth(8), Shannon L. Harris(6), Michael W. Pride(6), Gary W. Zlotnick(6), Christopher M. Haqq(6), Ingrid L. Scully(6), Susan K. Hoiseth(5), Thomas R. Jones(5), Lochana M. Seenappa(5), James Perry(5), Esther Welkowsky(5), Kathrin U. Jansen(5), Shubham Pant(4), Zev A. Wainberg(4), Pashtoon Murtaza Kasi(4), Craig Devoe(4), Vincent Chung(4)